|
Gene: C18orf21 |
Gene summary for C18ORF21 |
Gene summary. |
Gene information | Species | Human | Gene symbol | C18orf21 | Gene ID | 83608 |
Gene name | chromosome 18 open reading frame 21 | |
Gene Alias | HsT3108 | |
Cytomap | 18q12.2 | |
Gene Type | protein-coding | GO ID | NA | UniProtAcc | Q32NC0 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
83608 | C18orf21 | LZE7T | Human | Esophagus | ESCC | 1.34e-05 | 4.30e-01 | 0.0667 |
83608 | C18orf21 | LZE20T | Human | Esophagus | ESCC | 3.72e-02 | 7.36e-02 | 0.0662 |
83608 | C18orf21 | LZE24T | Human | Esophagus | ESCC | 1.58e-06 | 2.82e-01 | 0.0596 |
83608 | C18orf21 | P1T-E | Human | Esophagus | ESCC | 2.33e-05 | 2.05e-01 | 0.0875 |
83608 | C18orf21 | P2T-E | Human | Esophagus | ESCC | 3.05e-19 | 2.70e-01 | 0.1177 |
83608 | C18orf21 | P4T-E | Human | Esophagus | ESCC | 2.28e-14 | 3.90e-01 | 0.1323 |
83608 | C18orf21 | P5T-E | Human | Esophagus | ESCC | 8.67e-24 | 1.94e-01 | 0.1327 |
83608 | C18orf21 | P8T-E | Human | Esophagus | ESCC | 3.37e-13 | 9.70e-02 | 0.0889 |
83608 | C18orf21 | P9T-E | Human | Esophagus | ESCC | 7.70e-15 | 4.25e-01 | 0.1131 |
83608 | C18orf21 | P10T-E | Human | Esophagus | ESCC | 1.89e-14 | 1.78e-01 | 0.116 |
83608 | C18orf21 | P11T-E | Human | Esophagus | ESCC | 1.13e-02 | 1.46e-01 | 0.1426 |
83608 | C18orf21 | P12T-E | Human | Esophagus | ESCC | 3.30e-20 | 2.78e-01 | 0.1122 |
83608 | C18orf21 | P15T-E | Human | Esophagus | ESCC | 1.35e-14 | 3.53e-01 | 0.1149 |
83608 | C18orf21 | P16T-E | Human | Esophagus | ESCC | 4.31e-12 | 1.45e-01 | 0.1153 |
83608 | C18orf21 | P17T-E | Human | Esophagus | ESCC | 4.55e-07 | 2.09e-01 | 0.1278 |
83608 | C18orf21 | P19T-E | Human | Esophagus | ESCC | 2.27e-04 | 3.44e-01 | 0.1662 |
83608 | C18orf21 | P20T-E | Human | Esophagus | ESCC | 9.62e-10 | 3.00e-01 | 0.1124 |
83608 | C18orf21 | P21T-E | Human | Esophagus | ESCC | 4.51e-13 | 2.82e-01 | 0.1617 |
83608 | C18orf21 | P22T-E | Human | Esophagus | ESCC | 1.02e-21 | 4.43e-01 | 0.1236 |
83608 | C18orf21 | P23T-E | Human | Esophagus | ESCC | 5.09e-23 | 5.98e-01 | 0.108 |
Page: 1 2 3 4 5 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
C18orf21 | SNV | Missense_Mutation | c.350N>T | p.Ser117Ile | p.S117I | Q32NC0 | protein_coding | deleterious(0) | possibly_damaging(0.839) | TCGA-BH-A18J-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | PD | |
C18orf21 | insertion | In_Frame_Ins | novel | c.277_278insATA | p.Phe93delinsTyrIle | p.F93delinsYI | Q32NC0 | protein_coding | TCGA-AC-A3QQ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
C18orf21 | SNV | Missense_Mutation | c.129T>G | p.Cys43Trp | p.C43W | Q32NC0 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-C5-A1BM-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Unknown | Unknown | SD | |
C18orf21 | SNV | Missense_Mutation | novel | c.626N>C | p.Asn209Thr | p.N209T | Q32NC0 | protein_coding | tolerated(0.38) | benign(0.344) | TCGA-F5-6814-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
C18orf21 | SNV | Missense_Mutation | novel | c.331G>T | p.Val111Leu | p.V111L | Q32NC0 | protein_coding | tolerated(0.12) | benign(0.038) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
C18orf21 | SNV | Missense_Mutation | novel | c.616G>A | p.Asp206Asn | p.D206N | Q32NC0 | protein_coding | tolerated(0.13) | benign(0.357) | TCGA-AP-A1DK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
C18orf21 | SNV | Missense_Mutation | rs751025528 | c.326N>T | p.Arg109Ile | p.R109I | Q32NC0 | protein_coding | deleterious(0) | possibly_damaging(0.808) | TCGA-AP-A1DV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
C18orf21 | SNV | Missense_Mutation | c.552G>T | p.Lys184Asn | p.K184N | Q32NC0 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AX-A0J0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
C18orf21 | SNV | Missense_Mutation | novel | c.191N>T | p.Arg64Met | p.R64M | Q32NC0 | protein_coding | deleterious(0) | benign(0.346) | TCGA-AX-A2HD-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
C18orf21 | SNV | Missense_Mutation | c.603G>T | p.Lys201Asn | p.K201N | Q32NC0 | protein_coding | deleterious(0.03) | benign(0.027) | TCGA-D1-A103-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |